Dublin, Aug. 17, 2016 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Depression: Epidemiology and Patient-Based Market Forecasts, Treatment Algorithm, and Marketed and Pipeline Drug Analysis" report to their offering. The depression market is likely to recover from a new low in 2016, although the extent of its resurgence will depend on the fate of high-risk clinical trials. This report addresses the following questions: - How much value remains in the depression market, now that the patent cliff has passed? - As Lundbeck and Allergan go head-to-head in the SSRI and atypical antipsychotic classes, which of their new brands will become future market leaders? - What is the potential for Johnson & Johnson's esketamine as an antidepressant, considering its safety profile and regulatory barriers? - Which new and pipeline drugs address real unmet needs, contrasting with those that can be considered as me-too products? - How does real-world prescribing behaviour match treatment guidelines for major depression and dysthymia? Key Topics Covered: FORECAST: DEPRESSION - Executive Summary - Market Overview and Trends - Market Definition and Methodology - Abilify (aripiprazole) - Brintellix (vortioxetine) - Cymbalta (duloxetine) - esketamine - Fetzima (levomilnacipran) - Latuda (lurasidone) - Lexapro (escitalopram) - Pristiq (desvenlafaxine) - Rexulti (brexpiprazole) - Seroquel (quetiapine) - Viibryd (vilazodone) - Vraylar (cariprazine) - Primary Research Methodology TREATMENT: DEPRESSION - Executive Summary - Primary Research Methodology - Disease Definition and Diagnosis - Patient Segmentation - Country Treatment Trees - Current Treatment Options - Prescribing Trends - Unmet Needs in Depression EPIDEMIOLOGY: DEPRESSION IN THE US, JAPAN, AND 5EU - Executive Summary - Disease Background - Sources and Methodology - Forecast: Major Depressive Disorder - Forecast: Dysthymia - Epidemiologist Insight - Strengths and Limitations MARKETED DRUGS: DEPRESSION - Executive Summary - Product Overview - Product profile: Abilify - Product profile: Brintellix - Product profile: Cymbalta - Product profile: Fetzima - Product profile: Lexapro - Product profile: Pristiq - Product profile: Rexulti - Product profile: Seroquel XR - Product profile: Viibryd PIPELINE: DEPRESSION - Executive Summary - Clinical Pipeline Overview - Product profile (late stage): ALKS 54 - Product profile (late stage): Vraylar - Product profile (late stage): esketamine APPENDIX - Appendix: Marketed Drugs: Depression - Appendix: Pipeline: Depression For more information about this report visit http://www.researchandmarkets.com/research/hpjp9n/depression Related Topics: Mental Disorders Drugs
CONTACT: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716
